Phage Therapy Market – Overview (2026–2035)
Market Size & Forecast
- The global phage therapy market is projected to grow from USD 0.06 billion in 2026 to USD 0.22 billion by 2035.
- This represents a Compound Annual Growth Rate (CAGR) of about 17.6% over the forecast period.
What Is Phage Therapy?
- Phage therapy uses bacteriophages (viruses that infect bacteria) as treatments for bacterial infections.
- These therapies are considered promising alternatives to traditional antibiotics, especially against drug-resistant bacteria.
📦 Market Segmentation
By Type
- DsDNA Bacteriophage – Largest segment (~55% share) due to clinical effectiveness.
- SsDNA Bacteriophage – ~25% share, with interest in personalized medicine.
- SsRNA Bacteriophage – ~15% share, useful for targeting specific resistant bacteria.
- Others (including phages for non-medical uses like agriculture and food safety) – ~5%.
By Application
- Spread across Human Health, Animal Health, Aquaculture, Agriculture, the Food Industry, and others.
- Animal health is forecast to hold high share due to antibiotic alternatives in livestock.
🌍 Regional Insights
Global Geographic Shares
- North America: ~45% of the market, led by strong R&D and biotech investment.
- Asia-Pacific: ~35%, boosted by government support and antibiotic-resistance initiatives.
- Europe: ~15%, with growing collaborations between biotech and research institutions.
- Rest of World: ~5%, as awareness and adoption grow in Latin America, Africa, and the Middle East.
⚙️ Key Market Drivers
- Antibiotic Resistance: Increasing drug-resistant bacterial infections are driving demand for phage therapies as alternatives to traditional antibiotics.
- Clinical Advancements: Expanding research, clinical trials, and personalized phage solutions contribute to market growth.
🚧 Challenges and Restraints
- Limited Research & Awareness: A shortage of robust clinical data and familiarity among healthcare providers and patients slows adoption in some regions.
- Regulatory Barriers: Phage therapy approvals are limited in many markets.
🧠 Competitive Landscape – Key Players
The report lists several major companies involved in phage therapy development and commercialization, including:
- NPO Microgen (Russia)
- Proteon Pharmaceuticals (India)
- Phagelux (China)
- Intralytix (U.S.)
- Micreos (Netherlands)
- Eliava BioPreparations (Georgia)
- Locus Biosciences (U.S.)
- Pherecydes Pharma (France)
- Adaptive Phage Therapeutics (U.S.)
- Armata Pharmaceuticals (U.S.)
…and several others expanding phage therapy pipelines globally.
📌 Report Scope & Coverage
The full report (which requires purchase or sample download) includes:
- Detailed segmentation tables
- Forecasts by region and application
- Competitive analysis and company profiles
- Insights on trends, restraints, and growth opportunities
PHAGElogist 